Early descriptions of in vitro ACTH bioassays all emphasised the need to use extracted plasma samples due to interference by an unidentified component. The aim of these studies was to elucidate the effects of whole plasma on ACTH steroidogenic activity in vitro and to identify the responsible factor. A sensitive in vitro dispersed bovine adrenocortical cell bioassay was established. The addition of 10% ACTH-depleted human pooled plasma to the incubation media resulted in basal steroidogenesis equivalent to that achieved with 10 9 M ACTH 1-24 and potentiated the steroidogenic activity of 10 9 M ACTH 1-24 by 7·8-fold. This potentiation was dependent on the concentration of both ACTH and plasma in the media, but did not result from the mitogenic effect of plasma. A pituitary source was excluded and the potentiating activity was not extractable by Vycor glass. Column chromatography demonstrated two peaks of activity corresponding to molecular weights of 650 and 220 10 3 Da. These peaks did not correspond to the plasma binding of 125 I-ACTH which resulted from non-specific binding to albumin. Lipoprotein-deficient serum had no effect on either basal or ACTH-stimulated steroidogenesis, but both were restored by the addition of purified lipoproteins. However, novel findings demonstrated a differential effect of low (LDL) and high (HDL) density lipoproteins on basal and ACTH-stimulated steroid production; thus, LDL exerted a greater effect on the former, whilst HDL potentiated the steroidogenic activity of added ACTH more than LDL. The addition of the lipoproteins to lipoprotein-deficient serum restored its basal and ACTH potentiating effects, the cholesterol concentrations of the chromatographic fractions exactly paralleling their ACTH potentiating effect. These findings suggest that not only are lipoproteins the plasma factor(s) which potentiates ACTH steroidogenic activity in in vitro bioassays, but also that they exert differential effects on basal and ACTH-stimulated steroid production.
Introduction
Prior to the introduction of its RIA, measurement of circulating adrenocorticotropin (ACTH) required the use of bioassays, although all of these emphasised the need for extracted plasma samples. In the case of in vivo assays, such as that developed by Lipscomb and Nelson (1962) , this was to increase the assay sensitivity, whilst for in vitro bioassays, several workers observed that extraction was necessary to avoid interference in the assay by unidentified substances (Giordano & Sayers 1971 , Lowry et al. 1973 , Reader et al. 1982 , Lambert et al. 1984 . However, despite these observations, only a few preliminary attempts have been made to identify the responsible factor(s). Lowry et al. excluded prostaglandin E 2 , which had been shown to have an effect in perfused adrenal glands, and insulin, which had been shown to increase the adrenal binding of radiolabelled corticotropin (Lowry et al. 1973 , Rees et al. 1973 ). The modulatory effects of pro-opiomelanocortin (POMC) products other than ACTH, particularly with reference to the N-terminal region, have been investigated by a number of workers, but with conflicting results. Although N-POMC 1-76 has been shown to have a mild to moderate potentiating effect by some workers , Al-Dujaili et al. 1981 , such actions have not been confirmed by other studies (Pham-Huu-Trung et al. 1982 , Cathiard et al. 1985 .
One possible explanation for any potentiation of in vitro ACTH bioactivity by whole plasma is that it might be due to a specific ACTH binding protein that protects the peptide from proteolytic degradation. This was supported by Upton et al. (1970) who performed crude chromatographic separation of plasma into high (>4·5 kDa) and low (<4·5 kDa) molecular weight fractions after infusion of human and porcine ACTH. They observed that 82% of the bioactive human ACTH was in the high molecular weight fraction, compared with 31% of the porcine infusion plasma. Fehm et al. (1973) also suggested the presence of an ACTH binding protein and estimated its size to be 150-200 10 3 Da.
Thus, the existence of a substance in plasma that is capable of modulating the in vitro steroidogenic activity of ACTH has been documented by endocrinologists for over 20 years, but to date its identity has remained unknown. The aims of our investigation were: (1) to clarify the in vitro effect of human plasma on basal and ACTHstimulated glucocorticoid synthesis by adrenal zona fasiculata and reticularis cells, (2) to characterise and identify any modulatory plasma factors, and (3) to clarify the existence of a specific plasma ACTH binding protein.
Materials and Methods

Dispersed adrenal cell bioassay
An in vitro dispersed adrenocortical ACTH bioassay was established based on previously described methodology (Tait et al. 1980 , Bird et al. 1991 . Fresh bovine adrenal glands were obtained from an abattoir within 20 min of slaughter. Each gland was slowly perfused, via the adrenal artery, with 30 ml warm Earles' balanced salt solution (EBSS) to remove red corpuscles, cut in a sagittal direction and the yellow medullary tissue removed. The underlying zona reticularis and fasiculata were gently scraped off leaving a 1-mm rim comprising the zona glomerulosa and capsule. The tissue from each gland was incubated for 90 min at 37 C in 30 ml EBSS containing 2 mg/ml collagenase (Worthington Class 1; lot no. S4S088, Worthington Biochemical Corporation, Halls Mill Road, Freehold, NJ, USA). Any remaining clumps of tissue were further dispersed by vigorously bubbling air through the 50 ml tube using a Pipette-Aid; the resultant suspension was filtered over 250 µm nylon gauze and washed three times with warm EBSS. The number and viability of the dispersed cells was assessed using Trypan blue and a haemocytometer and cells were plated into 12-well plates at a concentration of 5 10 5 cells/well. One millilitre Ham's F12 medium, containing 10% fetal calf serum, penicillin 100 IU/ml, streptomycin 100 µg/ml and -amphotericin 0·25 µg/ml was added to each well, and incubated for 24 h at 37 C in 5% CO 2 . Cells were then washed twice with warm EBSS containing 0·2% bovine serum albumin (BSA), after which they were ready for stimulation with the substances under investigation. In each experiment, the final volume in each well was made up to 500 µl with EBSS+0·2% BSA. Stimulated cells were incubated for a further 24 h, after which the incubation medium was carefully removed and stored at 20 C prior to measuring the cortisol concentration by RIA. Using this protocol, the minimum detectable concentration of ACTH 1-24 was 5 10 12 M (34 pg/ml) with a maximum response occurring between 10 9 and 5 10 9 M. Similar results were obtained with ACTH 1-39 .
The intra-and interassay precisions for the steroidogenic effect of 10 9 M ACTH 1-24 were 8·3% and 67% respectively. Each study was performed in triplicate and each experiment repeated on three occasions. In order to overcome the interassay variability and to allow comparisons to be drawn between different experiments all values are expressed as a ratio of the steroidogenic effect of 10 9 M ACTH 1-24 which was used in each experiment.
Effect of human plasma on ACTH steroidogenic activity
Pooled plasma was used in which all the endogenous ACTH had been proteolytically cleaved by leaving at room temperature for 24 h, as evidenced by undetectable levels in an ACTH RIA. Ten percent by volume of plasma was added to the incubation media in each well, with and without ACTH 1-24 (final concentration 10 9 M). The effect of temperature was assessed by using plasma that had been heated to 37 C or 55 C for 12 h. Modulation by a POMC or pituitary factor was investigated by studying plasma samples from patients with (1) isolated ACTH deficiency, (2) panhypopituitarism following transsphenoidal surgery and (3) following the administration of dexamethasone to normal subjects (0·5 mg 6-hourly for 48 h); the mean ACTH levels before and after dexamethasone were 23 pg/ml and <10 pg/ml respectively.
The mitogenic effect of plasma was assessed by measuring the total DNA content of the wells, according to the method of West et al. (1985) .
Influence of Vycor glass extraction on ACTH potentiation
Three test samples (final volume 2 ml) were made up containing either 10% ACTH-deficient plasma, 10 8 M ACTH, or both combined. To each tube was added 1 ml silica glass 'Vycor' (previously activated by heating to 600 C for 1 h) suspension (50 mg/ml water) and after gentle mixing for 30 min at room temperature, the supernatant was removed and stored at 20 C. The remaining Vycor pellet was subjected to acid-acetone extraction with the extract being reconstituted in EBSS. Seventy-five microlitres of both the extracts and original supernatants were added to the assay wells with and without the addition of ACTH 1-24 (final concentration 10 9 M).
Estimation of the molecular weight of the modulatory factor
Chromatographic separation of plasma was performed using washed, degassed Sephacryl S300 (separation range of globular proteins of 10-1500 10 3 Da) in a 90 0·9 cm glass column. The eluant was EBSS+0·2% BSA at pH 7·4 passed at a rate of 6 ml/h with 1 ml fractions collected. The void volume (V 0 ) and total volume (V t ) were determined using dextran blue and 125 I-ACTH respectively and the column calibrated with known molecular weight markers (45-650 10 3 Da). After priming with plasma and equilibration for 48 h, 1 ml spun plasma was loaded onto the column. From each fraction 450 µl were added directly to the assay wells together with 50 µl 10 8 M ACTH; each fraction was assayed in duplicate.
Evaluation of an ACTH binding protein
Comparison was made of the radiochromatographic profiles after 125 I-ACTH had been incubated in plasma or EBSS and passed over the Sephacryl column. Both mixtures were incubated for 2 h at room temperature and eluted at a rate of 6 ml/h with 1 ml fractions collected. Subsequent experiments determined the effect of temperature (incubation at 4 C for 60 min) or mercaptoethanol upon the binding. The binding specificity was assessed by comparison with incubation in a physiological albumin solution (40 g/l) and the displacement by a 100-fold excess of 'cold' ACTH.
Specificity of plasma in potentiating ACTH-stimulated glucocorticoid synthesis
The specificity of the plasma potentiation to glucocorticoid secretion was assessed by the measurement of other adrenocortical hormones, androstenedione and testosterone, in the bioassay after stimulation by 10 9 M ACTH 1-24 and 10% plasma. Specificity to ACTH was assessed by observing the effects of plasma on glucocorticoid production in response to 10 8 and 10 9 M angiotensin II (AII).
Cholesterol as a modifier of ACTH steroidogenic activity
The influence of exogenous cholesterol upon the steroid production by the bioassay was assessed. Studies were performed using (1) lipoprotein-deficient serum (LPDS) and (2) purified high density (HDL) and low density (LDL) lipoproteins, prepared by density ultracentrifugation and membrane dialysation from the same plasma pool (Schumaker & Puppione 1986) . The cholesterol concentrations of the purified LDL and HDL were 15·7 and 9·9 mmol/l respectively. To each bioassay well was added 50 µl LPDS or LDL or HDL without and with the simultaneous addition of 50 µl 10 8 M ACTH 1-24 . Finally, comparison was made of the potentiating effect and the cholesterol content of the chromatographic fractions of plasma. Total cholesterol content was measured by an enzymatic assay (Nanjee et al. 1996) .
Results
Effect of human plasma on ACTH steroidogenic activity
Although on its own 10% plasma resulted in steroidogenesis equivalent to 10 9 M ACTH 1-24 there was a marked synergistic effect when it was combined with 10 9 M ACTH 1-24 , resulting in a 7·8-fold increase in cortisol production. There was no loss of basal or potentiating activity using plasma heated to either 37 C or 55 C. The potentiating effect was dependent on both the ACTH concentration and that of plasma, occurring with as little as 1% by volume. The addition of 20% and 50% plasma caused respectively a 1·6-and 3·2-fold increase in basal cortisol production compared with that from 10 9 M ACTH 1-24 , and a 9·6-and 20-fold increase in 10 9 M ACTH 1-24 -stimulated steroid secretion (Fig. 1) . The time course of the ACTH potentiation mirrored that of ACTH alone, both beginning within 30 min and reaching a maximum effect after 8 h incubation. A POMC or pituitary source of the potentiating factor was excluded because both the basal and ACTH potentiating activity of plasma from the three patient groups was the same as normal plasma.
That the potentiation was not a reflection of increased cell numbers was excluded by the DNA content of the wells. Although compared with 10 9 M ACTH 10% plasma on its own resulted in an increased DNA concentration, there was no further increase with the combination of plasma and ACTH. Figure 2 shows the potentiating effects of the extract and supernatant of plasma, ACTH or both combined on ACTH steroidogenic activity. As expected, the extract of the ACTH sample resulted in significant steroidogenesis, whilst the ACTH supernatant had minimal activity. In contrast, stimulation with the plasma extract resulted in little enhancement of steroidogenesis, whilst the supernatant resulted in a 3·1-fold potentiation. Estimation of the molecular weight of the potentiating factor Figure 3 is a representative graph of the potentiating effect of fractions 25-92 on ACTH 1-24 -stimulated steroidogenesis. Repeated experiments confirmed the findings. Two peaks of potentiation were obtained that corresponded to molecular weights of 650 10 3 and 220 10 3 Da respectively, but with the former being the more active.
Influence of Vycor glass extraction on ACTH potentiation
Evaluation of an ACTH binding protein
Column chromatography with radiolabelled ACTH showed that 125 I-ACTH 1-39 incubated with EBSS appeared after V t , whilst after incubation with plasma there was a sharp peak that appeared at fraction 74, corresponding to an approximate molecular weight of 40 10 3 Da. This binding was unaffected by temperature or mercaptoethanol. An identical peak of binding was obtained following incubation in albumin and there was no displacement by the addition of excess 'cold' ACTH 1-39 .
Specificity of plasma in potentiating ACTH-stimulated steroid synthesis 10 9 M ACTH stimulated the secretion of both androstenedione and testosterone into the medium, and secretion was potentiated 5·2-and 3·4-fold respectively by the addition of 10% plasma. Plasma also enhanced the production of cortisol in response to 10 8 and 10 9 M angiotensin-II by up to 18-fold.
The effects of cholesterol on ACTH steroidogenic activity
LPDS by itself caused no detectable steroidogenesis and no potentiation of ACTH. 10% LDL (final cholesterol concentration 1·57 mmol/l) resulted in basal steroidogenesis 0·6-and 0·47-fold respectively that obtained with 10% plasma and 10 9 M ACTH, whilst 10% HDL (final cholesterol concentration 1·0 mmol/l) was less potent, being 0·23-and 0·18-fold as effective respectively (Fig. 4) . However, an opposite pattern of results was observed in their potentiation of 10 9 M ACTH 1-24 steroidogenic activity with 10% LDL causing a 4-fold increase (0·4 times as potent as whole plasma), whereas 10% HDL potentiated the effects of ACTH 9·2-fold (0·9 times as effective as whole plasma) (Fig. 5) . In combination, their effects were additive with a 12·8-fold increase in steroid production. The cholesterol content of the chromatographic fractions paralleled their ACTH potentiating activity (Fig. 6 ).
Discussion
Although previous workers have suggested the existence of an ACTH binding protein (Fehm et al. 1972 , Nicholson et al. 1984 , our results suggest that such binding is due to non-specific interaction to albumin. Not only did the highest binding correspond to a molecular weight of approximately 40 10 3 Da, indistinguishable from that of albumin, but a similar peak was observed when 125 I-ACTH was incubated with a physiological concentration of albumin. Furthermore, plasma-bound 125 I-ACTH could not be displaced by the addition of excess 'cold' ACTH. These observations support those of Muramoto and Ramachandran (1981) who also documented binding of ACTH to albumin. We have provided strong evidence that the factor(s) in human plasma that potentiates its in vitro steroidogenic activity is cholesterol in the form of lipoproteins. These findings explain the majority of earlier reports using in vitro dispersed adrenal cell bioassays, in which human plasma was observed to alter the shape of the steroidogenic dose-response curve (Giordano & Sayers 1971 , Lowry et al. 1973 , Lambert et al. 1984 . The influence of lipoproteins on steroidogenesis has also been investigated by previous workers, although the majority of studies have been performed from a non-endocrinological perspective with the primary interest being directed towards the biochemistry of cholesterol per se and its subsequent uptake and metabolism, rather than the modulation of glucocorticoid secretion and synthesis. These studies on lipoprotein metabolism have revealed that LDL-cholesterol is preferentially utilised in mice (Faust et al. 1977) and human fetal cells , Carr et al. 1980 , Higashijima et al. 1987 , whilst HDL-cholesterol is the preferred substrate in rats (Gwynne et al. 1976 , Andersen & Dietschy 1978 , Gwynne & Hess 1980 . Studies using bovine adrenocortical cells have demonstrated variable results and few have directly compared the relative effects of HDL and LDL, although preincubation with either lipoprotein increased both basal and ACTH-stimulated steroidogenesis (Koper et al. 1985) . No difference between the two was observed in ACTH-stimulated steroid production, even at high ACTH concentrations (10 7 M) (Higashijima et al. 1987) , whilst another revealed HDL to have a greater effect on both basal and ACTH (10 7 M)-stimulated steroidogenesis (Yaguchi et al. 1998) . Kovanen et al. (1979) observed that LDL but not HDL increased basal production, but did not investigate their influence on ACTH. A 5-fold increase in ACTH-stimulated (50 nM) cortisol production was recorded with human LDL after prolonged stimulation but comparison with human HDL was not made (Rainey et al. 1992 ). In addition, HDL, but not LDL, has also been reported to increase basal and AII-stimulated mineralocorticoid production by bovine zona glomerulosa cells (Knorr et al. 1988 ). 
Figure 6
The cholesterol content and 10 9 M ACTH 1-24 enhancing activity of fractions obtained from chromatographic separation of plasma. Each value was performed in duplicate.
Our results from direct comparisons between LDL and HDL on basal and ACTH-stimulated steroid production are broadly in agreement with these studies (Koper et al. 1985 , Knorr et al. 1988 . We observed that both LDL and HDL increased basal secretion but with LDL being more potent, whilst opposite effects were observed on ACTHstimulated steroidogenesis with HDL having a greater effect. The mechanisms that might explain these novel differential effects are uncertain. Under basal conditions, LDL might be preferentially taken up by adrenocortical cells, via endocytic internalisation of its specific receptor . The existence of such a receptor for HDL remains controversial and although attachment to the plasma membrane does occur, free cholesterol is preferentially taken up (up to 8-fold greater) rather than the intact molecule and its associated lipoprotein (Simpson 1979 . Such uptake might be increased in the presence of ACTH.
An alternative explanation is that HDL is able to influence ACTH signal transduction. Alterations in membrane cholesterol:phospholipid ratio that influence its fluidity have been shown to affect membrane bound adenylate cyclase activity (Sinha et al. 1977 , Sinensky et al. 1979 , Whetton et al. 1983 ) and cause conformational transitions within the ACTH molecule that alter its interaction with the receptor (Nabedryk-Viala et al. 1978 , Gysin & Schwyzer 1984 . Functional studies have suggested that such alterations might have a physiological significance. Experimentally increasing the plasma membrane cholesterol:phospholipid ratio of adrenal cells, without adverse effects on cell viability, significantly increases production of ACTH-stimulated steroids and cAMP (Iida et al. 1987) . Whether such membrane effects explain our results remains unproven. It is known that there is a bidirectional flux of cholesterol between cells and lipoproteins and the binding of HDL to the cell membrane can promote the translocation of cholesterol to the plasma membrane from intracellular stores ( Johnson et al. 1986 , Slotte et al. 1987 . A combination of this and the preferential uptake of free cholesterol from HDL ) might result in the cholesterol enrichment of adrenocortical plasma membranes leading to changes in membrane fluidity and thus ACTH binding and receptor conformation. Some circumstantial evidence in support of this is the observation that whilst HDL is able to potentiate ACTH-stimulated steroidogenesis, it does not suppress intracellular ACTH-promoted induction of HMG CoA reductase, unlike LDL (Rainey et al. 1992) .
In conclusion, these observations suggest that lipoproteins are the principal constituents responsible for the interference by plasma of in vitro adrenocortical bioassays. In the absence of ACTH LDL is preferentially utilised for steroidogenesis, whilst in its presence HDL exerts a greater potentiating effect. The precise mechanisms for these differential effects remain to be determined.
